yes i take peptides · shopping companion

Semaglutide

Ozempic / Wegovy

Category · For Weight LossStatus · FDACitations · 60MTC Black Box

The verdict

The drug that changed the conversation. Weekly GLP-1 receptor agonist with a phase 3 weight-loss number around 14.9% and a 20% drop in major cardiovascular events in people with established heart disease.

By source — cost, legality, risk

Brand — Ozempic / Wegovy / Rybelsus
$199–$1,349/mo (NovoCare self-pay to retail list)
FDA-approved · prescription
Lowest. Real pharmacy product; NovoCare cuts to $199–$349/mo self-pay.
Compounded 503A pharmacy
$169–$499/mo
Prescription · off the FDA shortage list since May 2025
Mid. Pharmacy-grade, but supply now leans on 'personalization' workarounds.
RUO research peptide
$30–$100/mo
Sold 'for research only'
Highest. No purity guarantee — you reconstitute it yourself.
Gray-market raw
$1–$10/mo (amortized — minimum buy is one box)
Unregulated overseas import
Crypto/Wise pay, no published COA; cheapest per-mg path with largest variance.

Sources · top 5 of 60

01Smits MM, et al. Safety of Semaglutide. Frontiers in endocrinology. 2021;12:645563. PMID: 34305810.
02Chao AM, et al. Semaglutide for the treatment of obesity. Trends in cardiovascular medicine. 2023;33(3):159-166. PMID: 34942372.
03Davies M, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London, England). 2021;397(10278):971-984. PMID: 33667417.
04Tan HC, et al. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. Journal of the ASEAN Federation of Endocrine Societies. 2022;37(2):65-72. PMID: 36578889.
05Gabery S, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI insight. 2020;5(6). PMID: 32213703.